Cargando…

Targeted non AR mediated smart delivery of abiraterone to the prostate cancer

Prostate cancer is the second-deadliest tumor in men all over the world. Different types of drugs with various delivery systems and pathways were developed, but no one showed prominent results against cancer. Meanwhile, nanoparticles have shown good results against cancer. Therefore, in the given st...

Descripción completa

Detalles Bibliográficos
Autores principales: Baker, Abu, Khalid, Mohammad, Uddin, Imran, Khan, Mohd Sajid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416994/
https://www.ncbi.nlm.nih.gov/pubmed/36018864
http://dx.doi.org/10.1371/journal.pone.0272396
_version_ 1784776600406982656
author Baker, Abu
Khalid, Mohammad
Uddin, Imran
Khan, Mohd Sajid
author_facet Baker, Abu
Khalid, Mohammad
Uddin, Imran
Khan, Mohd Sajid
author_sort Baker, Abu
collection PubMed
description Prostate cancer is the second-deadliest tumor in men all over the world. Different types of drugs with various delivery systems and pathways were developed, but no one showed prominent results against cancer. Meanwhile, nanoparticles have shown good results against cancer. Therefore, in the given study, citrate mediated synthesized gold nanoparticles (CtGNPs) with immobilized survivin antibodies (SvGNPs) were bioconjugated to the substantially potent drug abiraterone (AbSvGNPs) to develop as a combinatorial therapeutic against prostate cancer. The AbSvGNPs are made up of CtGNPs, survivin antibodies, and abiraterone. The selected drug abiraterone (Abira) possesses exceptionally good activity against prostate cancer, but cancer cells develop resistance against this drug and it also poses several severe side effects. Meanwhile, survivin antibodies were used to deliver AbSvGNPs specifically into cancer cells by considering survivin, an anti-apoptotic overexpressed protein in cancer cells, as a marker. The survivin antibodies have also been used to inhibit cancer cells as an immunotherapeutic agent. Similarly, CtGNPs were discovered to inhibit cancer cell proliferation via several transduction pathways. The given bioconjugated nanoparticles (AbSvGNPs) were found to be substantially effective against prostate cancer with an IC50 of 11.8 and 7.3 μM against DU145 and PC-3 cells, respectively. However, it was found safe against NRK and showed less than 25% cytotoxicity up to 20μM concentration. The as-synthesized nanoparticles CtGNPs, SvGNPs, and AbSvGNPs were characterized by several physical techniques to confirm their synthesis, whereas the immobilization of survivin antibodies and bioconjugation of Abira was confirmed by UV-visible spectroscopy, DLS, TEM, FTIR, and zeta-potential. The anticancer potential of AbSvGNPs was determined by MTT, DAPI, ROS, MITO, TUNEL ASSAY, and caspase-3 activity against DU145 and PC3 cells.
format Online
Article
Text
id pubmed-9416994
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-94169942022-08-27 Targeted non AR mediated smart delivery of abiraterone to the prostate cancer Baker, Abu Khalid, Mohammad Uddin, Imran Khan, Mohd Sajid PLoS One Research Article Prostate cancer is the second-deadliest tumor in men all over the world. Different types of drugs with various delivery systems and pathways were developed, but no one showed prominent results against cancer. Meanwhile, nanoparticles have shown good results against cancer. Therefore, in the given study, citrate mediated synthesized gold nanoparticles (CtGNPs) with immobilized survivin antibodies (SvGNPs) were bioconjugated to the substantially potent drug abiraterone (AbSvGNPs) to develop as a combinatorial therapeutic against prostate cancer. The AbSvGNPs are made up of CtGNPs, survivin antibodies, and abiraterone. The selected drug abiraterone (Abira) possesses exceptionally good activity against prostate cancer, but cancer cells develop resistance against this drug and it also poses several severe side effects. Meanwhile, survivin antibodies were used to deliver AbSvGNPs specifically into cancer cells by considering survivin, an anti-apoptotic overexpressed protein in cancer cells, as a marker. The survivin antibodies have also been used to inhibit cancer cells as an immunotherapeutic agent. Similarly, CtGNPs were discovered to inhibit cancer cell proliferation via several transduction pathways. The given bioconjugated nanoparticles (AbSvGNPs) were found to be substantially effective against prostate cancer with an IC50 of 11.8 and 7.3 μM against DU145 and PC-3 cells, respectively. However, it was found safe against NRK and showed less than 25% cytotoxicity up to 20μM concentration. The as-synthesized nanoparticles CtGNPs, SvGNPs, and AbSvGNPs were characterized by several physical techniques to confirm their synthesis, whereas the immobilization of survivin antibodies and bioconjugation of Abira was confirmed by UV-visible spectroscopy, DLS, TEM, FTIR, and zeta-potential. The anticancer potential of AbSvGNPs was determined by MTT, DAPI, ROS, MITO, TUNEL ASSAY, and caspase-3 activity against DU145 and PC3 cells. Public Library of Science 2022-08-26 /pmc/articles/PMC9416994/ /pubmed/36018864 http://dx.doi.org/10.1371/journal.pone.0272396 Text en © 2022 Baker et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Baker, Abu
Khalid, Mohammad
Uddin, Imran
Khan, Mohd Sajid
Targeted non AR mediated smart delivery of abiraterone to the prostate cancer
title Targeted non AR mediated smart delivery of abiraterone to the prostate cancer
title_full Targeted non AR mediated smart delivery of abiraterone to the prostate cancer
title_fullStr Targeted non AR mediated smart delivery of abiraterone to the prostate cancer
title_full_unstemmed Targeted non AR mediated smart delivery of abiraterone to the prostate cancer
title_short Targeted non AR mediated smart delivery of abiraterone to the prostate cancer
title_sort targeted non ar mediated smart delivery of abiraterone to the prostate cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416994/
https://www.ncbi.nlm.nih.gov/pubmed/36018864
http://dx.doi.org/10.1371/journal.pone.0272396
work_keys_str_mv AT bakerabu targetednonarmediatedsmartdeliveryofabirateronetotheprostatecancer
AT khalidmohammad targetednonarmediatedsmartdeliveryofabirateronetotheprostatecancer
AT uddinimran targetednonarmediatedsmartdeliveryofabirateronetotheprostatecancer
AT khanmohdsajid targetednonarmediatedsmartdeliveryofabirateronetotheprostatecancer